

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
KOCHE ET AL.

Art Unit: 1626  
Examiner: Joseph R.  
Kosack

INTERNATIONAL APPLICATION NO: PCT/EP03/10171

FILED: 12 SEPTEMBER 2003

U.S. APPLICATION NO: 10/526,283

35 USC §371 DATE: 1 SEPTEMBER 2005

FOR: A NEW PROCESS FOR THE PREPARATION OF EPOTHILONE  
DERIVATIVES, NEW EPOTHILONE DERIVATIVES AS WELL AS  
NEW INTERMEDIATE PRODUCTS FOR THE PROCESS AND THE  
METHODS OF PREPARING SAME

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824

Date: May 8, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

KOCH ET AL.

Examiner: Joseph R. Kosack

APPLICATION NO: 10/526,283

FILED: SEPTEMBER 1, 2005

FOR: A NEW PROCESS FOR THE PREPARATION OF EPOTHILONE  
DERIVATIVES, NEW EPOTHILONE DERIVATIVES AS WELL AS  
NEW INTERMEDIATE PRODUCTS FOR THE PROCESS AND THE  
METHODS OF PREPARING SAME

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted



George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824  
Date: May 8, 2008